Latest news with #HarmonyBiosciencesHoldings
Business Wire
22-07-2025
- Business
- Business Wire
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
Yahoo
17-07-2025
- Business
- Yahoo
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Harmony Biosciences Holdings, Inc. (HRMY), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 23.53%. For the most recent quarter, Harmony Biosciences was expected to post earnings of $0.78 per share, but it reported $0.59 per share instead, representing a surprise of 32.20%. For the previous quarter, the consensus estimate was $0.74 per share, while it actually produced $0.85 per share, a surprise of 14.86%. Price and EPS Surprise With this earnings history in mind, recent estimates have been moving higher for Harmony Biosciences. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Harmony Biosciences currently has an Earnings ESP of +19.75%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner. Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric. Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15-07-2025
- Business
- Business Wire
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, July 17, 2025, at 10:00 a.m. ET. To register in advance, please use this link. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
Yahoo
10-07-2025
- Business
- Yahoo
Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise
Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts. On June 11, Harmony Biosciences Holdings presented promising preclinical pharmacological data for BP1.15205, which is an investigational orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of the Associated Professional Sleep Societies/APSS 'SLEEP' in Seattle. The data showed significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. Narcolepsy is a chronic neurological disease affecting ~170,000 Americans, primarily characterized by excessive daytime sleepiness/EDS and cataplexy, along with other manifestations of REM sleep dysregulation. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The disease is often caused by the loss of hypocretin/orexin, a neuropeptide crucial for sleep-wake stability. BP1.15205 features a new and unique chemical scaffold optimized for high potency, which showed statistically significant wake-promoting effects at very low oral doses in the transgenic mouse model. These findings support dosing flexibility to potentially treat all 3 central disorders of hypersomnolence at low doses, which could offer an optimized benefit-risk profile. Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops & commercializes therapies for patients with rare & other neurological diseases in the US. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10-07-2025
- Business
- Yahoo
H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 30, H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $70.00. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The company reported strong fiscal Q1 2025 results, with net revenue for WAKIX (pitolisant) in narcolepsy reaching $184.7 million for the quarter, reflecting a 20% year-over-year growth. It projects 2025 net revenue to be in the range of $820 to $860 million. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) also experienced a 19% year-over-year increase in net income, building on four consecutive years of profitability. It increased its cash and investments to more than $600 million on the balance sheet. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
